|
Originally published In Press as doi:10.1074/jbc.M104709200 on September 10, 2001
J. Biol. Chem., Vol. 276, Issue 45, 41825-41831, November 9, 2001
RNA Polymerase II-dependent Positional Effects on
mRNA 3' End Processing in the Adenovirus Major Late Transcription
Unit*
Deepika
Ahuja,
David S.
Karow,
Jay E.
Kilpatrick, and
Michael J.
Imperiale
From the Department of Microbiology and Immunology and
Comprehensive Cancer Center, University of Michigan Medical School,
Ann Arbor, Michigan 48109
Received for publication, May 23, 2001, and in revised form, September 6, 2001
 |
ABSTRACT |
During the early phase of adenovirus infection,
the promoter-proximal L1 poly(A) site in the major late transcription
unit is used preferentially despite the fact that the distal L3 poly(A) site is stronger (i.e. it competes better for processing
factors and is cleaved at a faster rate, in vitro).
Previous work had established that this was due at least in part to the
stable binding of the processing factor, cleavage and polyadenylation
specificity factor, to the L1 poly(A) site as mediated by specific
regulatory sequences. It is now demonstrated that in addition, the L1
poly(A) site has a positional advantage because of its 5' location in the transcription unit. We also show that preferential processing of a
particular poly(A) site in a complex transcription unit is dependent on
RNA polymerase II. Our results are consistent with recent reports
demonstrating that the processing factors cleavage and polyadenylation
specificity factor and cleavage stimulatory factor are associated with
the RNA polymerase II holoenzyme; thus, processing at a weak
poly(A) site like L1 can be enhanced by virtue of its being the
first site to be transcribed.
 |
INTRODUCTION |
The maturation of mRNA in eukaryotic cells is a complex
process in which the pre-mRNA is spliced, cleaved, and
polyadenylated. In most cases only one mRNA is produced from each
transcription unit. In these simple transcription units, 3' end
processing (cleavage and polyadenylation) is largely dependent upon a
series of cis-acting signals (for reviews see Refs. 1-3).
These signals include a well conserved hexanucleotide sequence, AAUAAA,
which is located 10-35 nucleotides upstream of the cleavage site, and
a less conserved G/U- or U-rich region, which is found 20-50
nucleotides downstream of the cleavage site. Cleavage occurs between
these two elements and is generally on the 3' side of an A residue (4).
Cleavage and polyadenylation specificity factor
(CPSF)1 binds to the AAUAAA
hexanucleotide, whereas cleavage stimulatory factor (CstF) interacts
with the less conserved downstream sequence as well as with CPSF (5).
CPSF is required for initial recognition of the substrate and for
cleavage and polyadenylation (6-11), whereas CstF enhances processing
efficiency by interacting with the CPSF·RNA complex and stabilizing
it (8, 12-14). Together with other factors such as CF1, CF2, poly(A)
polymerase, and poly(A)-binding protein II, the CPSF·CstF complex
catalyzes cleavage of the pre-mRNA (7, 8, 11, 15, 16). Poly(A)
polymerase then adds a poly(A) tail of roughly 200-250 residues to the
newly processed 3' end in a CPSF-dependent reaction (17).
CPSF and CstF co-localize with sites of transcription in the nucleus
(18), suggesting that pre-mRNA processing is closely linked to
transcription. Indeed, CPSF has been shown to be recruited to the
initiation complex by transcription factor IID (19). The integration of
processing and transcription is supported further by results
demonstrating that processing is dependent on the carboxyl-terminal
domain (CTD) of the largest subunit of RNA polymerase II (pol II)
in vivo (20) and in vitro (21) and that both CPSF
and CstF form a complex with the CTD (20).
Although most transcription units are simple and contain only one
poly(A) site, others have multiple poly(A) sites and/or splice sites.
These complex transcription units are capable of producing multiple
mRNAs from a single promoter. Recent evidence suggests that
promoter structure can modulate the recruitment of serine/arginine-rich
(SR) proteins, which also associate with the CTD, and thus control
splice site selection (22). Alternative RNA processing can be an
important part of the regulation of gene expression in complex
transcription units, resulting in tissue-specific and temporal
regulation of transcripts (for review see Ref. 23). For example,
sex-specific splicing of the Drosophila tra
pre-mRNA controls sexual differentiation (24, 25), and
tissue-specific alternative processing of the calcitonin pre-mRNA
produces functionally different proteins (26). Moreover, alternative 3'
end processing determines whether the membrane-bound or the secreted
form of the mouse immunoglobulin heavy chain is produced (27-29).
Poly(A) site strength and position in the transcription unit is thought to be responsible at least in part for this differential processing (30, 31).
Complex transcription units are also found in adenovirus. Because the
adenovirus DNA genome is only 36 kb, it needs to encode a large amount
of information in a relatively small space. This was accomplished by
the evolution of a number of differentially regulated complex
transcription units, which increase the pool of possible transcripts
adenovirus can express (32). The most well characterized of these is
the major late transcription unit (MLTU), which encodes the structural
proteins produced during the late phase of infection (for review see
Ref. 33). The MLTU consists of five families of gene products, L1-L5,
each with its own poly(A) site. The first poly(A) site, L1, is 8 kb
from the promoter, whereas the last site, L5, is over 26 kb from the
promoter. Through differential selection of a poly(A) site, followed by alternative splicing within each family (34), the MLTU can produce ~20 different transcripts.
Previous work has demonstrated that the L1 poly(A) site is used
predominantly early in infection (prior to viral DNA replication), whereas, late in infection (after the onset of viral DNA replication), all of the poly(A) sites are used almost equivalently (34-37). This
late processing pattern occurs despite the fact that a poly(A) site can
be used as soon as it is transcribed (34). Indeed, because L1 is the
first poly(A) site to be transcribed, one might expect that it would
have a positional advantage and be processed preferentially at all
times. One model to account for this contradiction is that the distal
sites compete better for processing factors, compensating for their
position in the transcription unit. Indeed, previous work has
demonstrated that, in trans, the L3 poly(A) site is
processed at a faster rate than the L1 site and is a stronger competitor for processing factors (38). Thus, it is conceivable that
early in infection the L1 poly(A) site has a positional advantage and
is used preferentially despite the presence of stronger sites downstream. This hypothesis is supported by some evidence, but that
evidence is not conclusive.
Although past work has examined processing rates and factor binding at
the L1 and L3 poly(A) sites on separate transcription units, these
studies did not examine the behavior of these poly(A) sites in
cis on the same transcription unit. Therefore, to further characterize the mechanism of alternative 3' end processing, we have
examined the processing patterns of transcription units containing the
L1 and L3 poly(A) sites in tandem. Our results indicate that in
cis the 5' L1 poly(A) site is favored or used roughly
equivalently to the distal L3 poly(A) site, and that this effect is
dependent upon ongoing transcription by RNA pol II. We conclude that
the position of a poly(A) site in the transcription unit can play an
important role in governing the use of that site.
 |
EXPERIMENTAL PROCEDURES |
Reagents--
Enzymes were purchased from New England Biolabs,
Life Technologies, Inc., and Promega. Radiochemicals were obtained from
Amersham Pharmacia Biotech.
Cell Culture--
Human 293 cells were propagated as monolayers
in Dulbecco's modified Eagle's medium supplemented with 10% fetal
calf serum. HeLa cells were grown in spinner flasks in Joklik-modified
minimum essential medium supplemented with 5% calf serum.
Plasmids and Bacteria--
All plasmids were grown in DH5 ,
except for L3L1 plasmids, which were grown in JM109. pML1+170-L3, which
contains the L1 and L3 poly(A) sites in a eukaryotic transcription unit
(39), was used in the transcription-processing reactions (40).
pGL1+170-L3, which was used to produce T7 RNA polymerase synthesized
pre-mRNA, was created by cloning the XbaI fragment
containing the L1 and L3 poly(A) sites from pML1+170-L3 into the
XbaI site in pGEM-3Zf(+). pML1+170-KL3 is the same as
pML1+170-L3, except that it contains a spacer between the L1 and L3
poly(A) sites. This plasmid was created by cloning a 429-base pair
KpnI fragment, derived from the L3 region and contiguous to
the 5' end of the L3 fragment already present, into the KpnI
site that exists between the L1 and L3 poly(A) sites. pML3-L1+170 and
pGL3-L1+170 are the same as pML1+170-L3 and pGL1+170-L3, respectively,
except that the order of the L1 and L3 poly(A) sites has been reversed
so that the L3 site is in the 5' position and the L1 site is in the 3' position. These were constructed as follows. The XbaI
fragment that contains the L1 and L3 poly(A) sites was isolated from
pGL1+170-L3, and its ends were then filled in using the Klenow fragment
of DNA polymerase I and ligated in a dilute reaction. The ligated circular product was then digested with KpnI, which cuts
between the L1 and L3 sequences, and used as a template for a
polymerase chain reaction in which primers with XbaI
restriction sites were used to amplify the now reversed poly(A) sites.
This fragment was then ligated into the XbaI site of dlpMLP6
(41) and pGEM-3Zf(+), making pML3-L1+170 and pGL3-L1+170, respectively.
The structures of these plasmids were verified by sequencing.
pMmL1+170-L3 is the same as pML1+170-L3, except for a modification in
the L1 poly(A) site. The conserved hexanucleotide AATAAA was mutated to
AATGAA (42) using a polymerase chain reaction-based protocol.
Additionally, an EcoRI site was introduced contiguous to the
hexanucleotide so as to facilitate sequence verification by restriction
digest. pL1SV contains an SV40 poly(A) site in place of the L1 and L3 sites, but retains sequences upstream of the L1 site such that it is
still recognized by the S1 probes (39). Total RNA isolated from cells
transfected with this plasmid was added to samples after the processing
reactions were complete, to control for poly(A)+ mRNA
recovery through the rest of the experimental procedures.
Nuclear Extract--
Nuclear extract was prepared from
exponentially growing HeLa cells as described (43) with the following
modifications: 4-(2-aminoethyl)benzenesulfonyl fluoride was added to
buffer C to 1 mM and to buffer D to 0.1 mM, and
the extract was dialyzed for 2.5 h in a 200-fold excess volume of
buffer D.
RNA Substrates--
2 µg of linearized template DNA was
incubated with 150 units of T7 RNA pol in a 50-µl reaction containing
40 mM Tris (pH 8.0), 25 mM NaCl, 8 mM MgCl2, 2 mM spermidine, 2.8 mM cap analog (m7G(5')ppp(5')G; Amersham
Pharmacia Biotech), 5 mM dithiothreitol, 5 µCi of
lyophilized [3H]UTP, 100 µM GTP, and 1 mM each ATP, UTP, and CTP at 18 °C for 3 h.
Reactions were stopped by addition of 2 µl of Promega RQ1 DNase (1000 units/ml), followed by incubation at 37 °C for 15 min. The RNA yield
was determined by the amount of tritiated UTP incorporated into
trichloroacetic acid-precipitable counts. pGL1+170-L3 was linearized
with HincII, which cuts in the polylinker downstream of the
distal poly(A) site, and then was used to synthesize L1L3 pre-mRNA.
L1 pre-mRNA was transcribed from pGL1+170-KL3 that had been
digested with NruI and HincII to remove the L3
sequences. L3 pre-mRNA was transcribed from pGL3-L1+170 that had
been treated with EcoRV and HincII to remove the
L1 sequences.
In Vitro Reactions--
All in vitro reactions were
performed under conditions in which the amount of product was directly
proportional to the input DNA or RNA, i.e.
all-trans-acting factors were in excess.
Transcription-processing reactions were performed by incubating 1 µg
of supercoiled substrate DNA at 30 °C for 2 h in a 50-µl reaction containing 110 µg of nuclear extract, 3% polyvinyl alcohol, 20 mM creatine phosphate, 2 mM
MgCl2, and 600 µM each GTP, ATP, UTP, and
CTP. When T7 RNA pol was being assayed, the reaction mixture also
contained 80 units of T7 RNA pol and 1 µg/ml -amanitin.
The -amanitin chase experiment was carried out by setting up
transcription-processing reactions as described above; however, after
incubation at 30 °C for 1 h, 1 µg/ml -amanitin was added and the reaction mixtures were incubated for an additional 1 or 2 h. As controls, transcription-processing reaction mixtures were incubated for 3 h at 30 °C in the absence or presence of 1 µg/ml -amanitin. All reactions were quenched by addition of an
equal volume of stop buffer (50 mM Tris, 50 mM
EDTA, and 0.1% SDS) and 30 µg of proteinase K, and then incubated at
37 °C for 15 min. RNA was extracted once with phenol and
chloroform/isoamyl alcohol and once with chloroform/isoamyl alcohol,
then precipitated by addition of ammonium acetate to 2.5 M,
25 µg of yeast tRNAPhe, and two volumes of ethanol. The
pelleted RNA was resuspended in TE buffer containing RNA (4 µg)
isolated from pL1SV-transfected cells (to serve as an internal control)
then loaded on oligo(dT)-cellulose columns to isolate
poly(A)+ RNA.
In vitro processing of T7 RNA pol-transcribed
pre-synthesized mRNAs was carried out for 2 h at 30 °C in
50-µl reaction mixtures, which contained 2 mM
MgCl2, 3% polyvinyl alcohol, 20 mM creatine phosphate, 1 mM ATP, 110 µg of nuclear extract, and 2 nM (100 fmol) pre-mRNA. The reactions were quenched,
and RNA was extracted as described above for the
transcription-processing reactions.
DNA Transfection and RNA Isolation--
Transient-transfection
assays were performed as described previously (44). The cells in each
10-cm2 dish were transfected with 10 µg of test plasmid
and 10 µg of sonicated salmon sperm DNA. RNA was isolated from the
transfected cells either by the acid guanidinium
thiocyanate-phenol-chloroform extraction method (45) or using the
NucleoSpin RNA II kit from CLONTECH.
S1 Nuclease Analysis--
Poly(A)+ RNA from nuclear
extract reactions or from transfections was isolated by
oligo(dT)-cellulose chromatography and analyzed with a DNA probe made
from the corresponding plasmid. To make these probes, a fragment
spanning the poly(A) site(s) from each plasmid was purified and 3'
end-labeled at the XbaI site upstream of the proximal
poly(A) site using the Klenow fragment of DNA polymerase I and
[ -32P]dCTP. Hybridizations and S1 digestions were
performed as described previously (44). ML1L3, L1L3, and L1KL3 RNA's
were hybridized at 60 °C and L3L1 RNAs at 58 °C. The predicted
sizes of protected bands are indicated in Fig. 1. Results were
quantitated with a Molecular Dynamics PhosphorImager after the products
of the S1 digestion were resolved on 6% polyacrylamide, 8 M urea gels.
 |
RESULTS |
A Promoter-proximal Weak Poly(A) Site Is Processed to a Greater
Extent than a Distal, Strong Poly(A) Site--
Our investigation of
the effects of position on processing was conducted using constructs
containing L1 and L3 poly(A) sites incubated in an uninfected HeLa cell
nuclear extract. Previous experiments in which processing at these
poly(A) sites was evaluated in trans demonstrated that the
L3 poly(A) site competes better for processing factors and is cleaved
at a faster rate than the L1 poly(A) site (38). To ensure that we could
reproduce this observation in our system, we performed processing
reactions in which either an L1 or an L3 pre-mRNA was used as a
substrate (Fig. 2A, lanes 1 and 4). We
also performed a competition assay in which equal amounts of L1 and L3
pre-mRNA were incubated in the same processing reaction
(lanes 2 and 3). Because both probes in this experiment were end-labeled to the same specific activity, we could
directly compare processing at the L1 and L3 sites. Whether the two
sites were assayed alone or together, processing at the L3 poly(A) site
was greater.
Previous results from coupled transcription-processing reactions in an
uninfected HeLa cell nuclear extract, however, demonstrated that when
the L1 and L3 poly(A) sites were in cis on the same transcription unit, the L1 site was used preferentially (40). This
accurately reflects the behavior of these sites in early infected HeLa
cells using an identical construct (41). One possible explanation for
the apparent inconsistency is that, when the L1 and L3 poly(A) sites
compete in cis, the L1 site has a positional advantage
because it is the first site to be transcribed, and is therefore the
first site available to the processing factors. If this explanation is
correct and position is important, moving the distal L3 poly(A) site
farther downstream should result in a relative increase in processing
at the proximal L1 poly(A) site. This is because the increase in
spacing would allow the proximal poly(A) site more time to interact
with the processing factors before the distal site is transcribed. To
evaluate this hypothesis, we designed mini-MLTUs (constructs containing
the major late promoter (MLP) driving only the L1 and L3 poly(A) sites)
in which the L3 poly(A) site was moved farther downstream by inserting
a 429 nucleotide spacer between the L1 and L3 poly(A) sites. We
performed transcription-processing reactions in a HeLa cell nuclear
extract in the presence and absence of this spacer (L1KL3 and L1L3
mini-MLTUs, respectively; Fig. 1).
Following incubation in the nuclear extract, poly(A)+
transcripts were isolated and analyzed by S1 nuclease protection assay
(Fig. 2, B and C).
In the absence of the spacer, the ratio of transcripts processed at the
L1 poly(A) site to those processed at the L3 poly(A) site (L1:L3) was
2.5 (lane 1), whereas in its presence the ratio was 7.2 (lane 2). Thus, the presence of the spacer in the mini-MLTU
caused preferential L1 poly(A) site use to increase almost 3-fold,
supporting the hypothesis that a 5' poly(A) site has a positional
advantage in the transcription unit. To confirm that processing in a
nuclear extract reaction is representative of processing in intact
cells, we transfected 293 cells with the L1L3 and L1KL3 mini-MLTUs,
analyzed the isolated poly(A)+ RNA by S1 nuclease
protection assay, and compared the results with those of the in
vitro reactions (Fig. 2C). The ratio of L1:L3 poly(A)
site use was similar in both the transfection and the transcription-processing assays using either L1L3 or L1KL3
mini-MLTU.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 1.
Plasmid maps of mini-MLTUs encoding the L1
and L3 poly(A) sites. The vector dlpMLP6 (41) used for expression
of the mini-MLTUs contains the leftmost 5,580 base pairs of the Ad5
sub360 genome (solid bars), including the
adenovirus type 2 major late transcription control region
(MLTCR), except that the E1B promoter and E1A poly(A) site
are deleted (striped bar). The L1 and L3 poly(A)
sites were inserted into the XbaI site of dlpMLP6, forming
the various mini-MLTUs. Shown for the mini-MLTUs are adenovirus L1
sequences (open box), L3 sequences
(hatched box), the L3 spacer (circle-filled
box), which is denoted by a K in the construct names,
and the SV40 early poly(A) site (cross-hatched
box). The arrows indicate the cleavage and
polyadenylation sites of the proximal (pA1) and distal
(pA2) poly(A) sites. The asterisk in the mL1L3
construct represents the mutation in the AATAAA sequence. Restriction
sites: E, EcoRI; X, XbaI.
The sizes (in nucleotides) of the protected products and the probe for
each S1 analysis are shown on the right.
|
|

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 2.
Processing at the L1 and L3 poly(A) sites in
the presence or absence of transcription. A, reactions
with poly(A) sites in trans. Lanes 1 and 4 show
the results from processing reactions in which either L1 or L3
pre-mRNA (4 nM) was used as a substrate. Lanes
2 and 3 show the results from processing reactions in which both
L1 and L3 pre-mRNAs (4 nM each), were used as
substrates. The positions of the S1 reaction products as a result of
input and processed RNAs are indicated on the right.
B, reactions with poly(A) sites in cis.
Transcription-processing reactions using mini-MLTUs as substrates were
performed as described under "Experimental Procedures."
Poly(A)+ transcripts were analyzed by S1 nuclease
protection assay. Filled circles indicate
transcripts cleaved at the proximal poly(A) site, whereas
arrowheads indicate transcripts cleaved at the distal
poly(A) site. C, quantification of results. The L1:L3 ratio
or L3:L1 ratio was plotted for nuclear extract reactions
(TP) and/or transfections (293). The ratios are
the means of at least three independent experiments. D,
recovery of processing at a distal poly(A) site in the absence of an
upstream competing poly(A) site. L1L3 or mL1L3 constructs were
transfected into 293 cells (lanes 1 and 2) or
incubated in a HeLa cell nuclear extract (lanes 3 and
4). Poly(A)+ transcripts were analyzed as above.
The positions of the L1 and L3 RNA products, those from the L1SV
control RNA, and undigested probe are indicated on the
right.
|
|
If the 5' poly(A) site has such an advantage, moving the L3 poly(A)
site from a distal position to a proximal one should result in a
relative increase in processing at the L3 site. To test this hypothesis, we reversed the poly(A) sites in the L1L3 construct, creating an L3L1 mini-MLTU, which we then used as a substrate in
transcription-processing reactions (Fig. 2B). With the L1L3 construct, the ratio of L1:L3 RNA was 2.5 (lane 1); however,
with the L3L1 construct, the ratio of L1:L3 RNA was only 0.023 (lane 3). Thus, there is a 100-fold increase in relative
processing at the L3 site when it is moved from the distal position to
the proximal one, probably reflecting the inherent strength of the L3
poly(A) site along with its 5' position. In 293 cells transfected with
the L3L1 construct, processing was undetectable at the L1 poly(A) site
and was observed only at the L3 site (data not shown).
The results described above indicate that the distal L3 poly(A) site is
processed to a lower extent because it is transcribed after the L1
poly(A) site; however, it is possible that the low processing
efficiency is the result of simple distance from the 5' end of the
pre-mRNA. To examine this possibility, we introduced a mutation in
the AATAAA hexanucleotide sequence at the L1 poly(A) site in an L1L3
construct (mL1L3) such that processing can no longer occur at the L1
site (42). We performed transcription-processing assays using L1L3 and
mL1L3 substrates, and we measured relative processing efficiencies
(Fig. 2D, lanes 3 and 4). We observed that the L3 site in mL1L3 is processed twice as much as the L3 site in
L1L3, indicating that, in the absence of an upstream competing poly(A)
site, the distal poly(A) site is processed to a greater extent. We
noted, however, that the mutation in the L1 poly(A) site did not result
in quantitative recovery of processing at L3, i.e. the total
amount of processing of the mL1L3 construct was only 50-80% of the
total processing of the L1L3 construct. A similar result was obtained
when we analyzed RNA isolated from 293 cells that were transfected with
either L1L3 or mL1L3 (lanes 1 and 2). These
observations suggest that, although relative position in a construct is
important, absolute distance from the 5' end also might play a role in
affecting processing efficiency. In addition, incomplete recovery of
processing at L3 in the mL1L3 construct could be caused by a repressor
activity in the L1 sequence, which was shown to be independent of the
AAUAAA hexanucleotide and is localized in a cis-acting
sequence upstream of the L1 poly(A) site (46).
Although the ratios from the nuclear extract experiments are consistent
with the ratios from the transfection assays, it is possible that the
higher level of RNA processed at the proximal poly(A) site in
vitro could have resulted from a second processing event on a
single pre-mRNA, i.e. during incubation in the extract pre-mRNAs were first processed at the distal poly(A) site and then
processed again at the proximal site. To test this possibility, we
examined processing of L1 and L3 poly(A) sites in a HeLa cell nuclear
extract using an -amanitin chase to inhibit further RNA pol II
transcription (47); hence, in the presence of -amanitin, only those
transcripts that are already synthesized would be processed (Fig.
3A, compare lanes 1 and 5). If secondary processing events were taking place,
then an increase in L1 processing would be seen relative to processing
of the L3 poly(A) site after -amanitin was added to the reaction
mixture. Our results (Fig. 3, A and B) suggest
that such secondary processing does not occur. The L1L3 construct was
incubated in the nuclear extract for 1 h, following which either
the reaction was stopped or -amanitin was added and the incubation
continued for an additional 1 and 2 h. In the absence of
-amanitin, products accumulate linearly over this time
period.2 The ratio of
processing at the L1 poly(A) site after and before the -amanitin was
added is 1.88 ± 0.48 (after 1 h), whereas that of the L3
poly(A) site is 1.67 ± 0.25 (after 1 h). The same is true
for the 2-h time point. The similarity in these ratios suggests that,
once a transcript is made, it is processed only once. Additional evidence for this conclusion comes from the finding that the L1:L3 ratio is higher in the L1KL3 construct than in the L1L3 construct, and
there is no reason to expect that increasing the distance between the
two poly(A) sites would result in more secondary processing. Indeed, it
appears that pre-mRNAs from complex transcription units are not
processed more than once in the nuclear extract and that, consequently,
the preferential processing of the proximal poly(A) site that we detect
is a result of its position relative to the promoter.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 3.
Secondary processing events do
not occur on L1L3 pre-mRNA. A, -amanitin chase
experiment. Transcription-processing reaction mixtures were first
incubated in the absence of -amanitin for 1 h at 30 °C
(lanes 2-4), then in the presence of 1 µg/ml -amanitin
for an additional 0 h (lane 2), 1 h (lane
3), or 2 h (lane 4). Control reaction mixtures
were incubated in the absence (lane 1) or presence
(lane 5) of -amanitin for 3 h at 30 °C. All
reaction mixtures were then subjected to S1 nuclease analysis. The
positions of the L1 and L3 RNA products, those from the L1SV control
RNA, and undigested probe are indicated on the right.
B, quantification of results. The relative increase in
processing at the L1 (open bar) and L3
(solid bar) poly(A) sites was quantified 1 and
2 h after the inhibition of transcription. The ratios are the
means of three independent experiments.
|
|
The Processing Pattern Is Altered on T7 RNA Polymerase
Transcribed Pre-mRNA--
We next determined whether or not the
positional effect might be related to association of processing factors
with RNA pol II. To address this question, we compared processing
efficiencies of poly(A) sites that had been transcribed by either RNA
pol II or T7 RNA pol. We chose T7 RNA pol because this polymerase lacks a CTD and hence should be unable to bind processing factors CPSF and
CstF (48). Transcription by T7 RNA pol alone was effected by the
addition of -amanitin to the nuclear extract to inactivate the
endogenous RNA pol II. When the linearized T7 promoter-driven L1L3 construct (pGL1+170-L3) was incubated with nuclear extract in the
absence of T7 RNA pol and -amanitin, the L1 and L3 poly(A) sites were processed in the same ratio as the L1 and L3 poly(A) sites
driven by the MLP in the pML1+170-L3 construct, i.e.
processing at the proximal L1 site was 3-fold that at the L3 site (Fig.
4, compare lanes 2 and
4). This result indicates that the processing machinery
interacts similarly with both L1L3 pre-mRNAs when transcribed by
RNA pol II. Although we have not determined the 5' end of the L1L3
pre-mRNA generated by RNA pol II from the pGL1+170-L3 construct, we
assume that transcription was initiated from the T7 promoter based on
previous reports (49, 50). In contrast, when T7 RNA pol was used to
transcribe pGL1+170-L3 in an -amanitin-treated nuclear extract, the
transcripts were processed almost exclusively at the distal L3 site
(lane 1). This result indicates that preferential processing
at the 5'-proximal site is not a consequence of transcription per
se, but is specific to transcription by the RNA pol II holoenzyme. Furthermore, the observed preferential processing of the L3 site in T7 RNA pol-synthesized pre-mRNAs in this experiment supports our
earlier argument that each RNA gets processed only once. In addition to
the bands corresponding to RNAs processed at the L1 and L3 sites, there
are other bands that we have not as yet characterized fully (Fig. 4,
lane 1), but which are consistent with products resulting
from termination by T7 RNA pol as they can also be detected in the
poly(A) fraction (data not shown). The L1 and L3 bands do
not appear to be termination products as they are not detected in the
poly(A) fraction.

View larger version (52K):
[in this window]
[in a new window]
|
Fig. 4.
Processing of T7 RNA pol-synthesized
transcripts. The indicated L1L3 construct (T7 promoter-driven in
lanes 1-3 and MLP-driven in lanes 4 and
5) was incubated for 2 h in a HeLa cell nuclear
extract, as described in the text. Poly(A)+ transcripts
were analyzed by S1 nuclease protection assay. The positions of the L1
and L3 RNA products, those from the L1SV control RNA, and undigested
probe are indicated on the right.
|
|
 |
DISCUSSION |
The work presented in this report suggests that relative position
in a complex transcription unit plays an important role in governing
poly(A) site use. Analysis of poly(A)+ transcripts isolated
from nuclear extract reactions and 293-transfected cells showed that
the proximal L1 poly(A) site was favored over the distal L3 poly(A)
site. This occurred despite the fact that the L3 poly(A) site is an
inherently stronger poly(A) site (Ref. 38 and Fig. 2A). Our
results are in agreement with previous in vivo data showing
that an increase in spacing between two poly(A) sites results in a
greater preference for the 5' site (51), although these investigators
studied an artificially duplicated single poly(A) site whose use is not
normally regulated. Our data implicate a role for RNA pol II and are
consistent with reports demonstrating that both CPSF and CstF bind to
the RNA pol II holoenzyme (20) and that the CTD of RNA pol II enhances
the cleavage reaction (21); hence, the processing machinery processes
to a greater extent the site that is transcribed first. Especially in
light of these findings, one would expect the proximal poly(A) site to
have a distinct temporal advantage that is dependent upon active transcription. Indeed, Manley et al. (52) have previously
reported that processing at the L1 site is a co-transcriptional event. Additionally, we have demonstrated here that preferential processing of
the proximal, but weak, L1 poly(A) site is dependent upon RNA pol II,
such that altering the polymerase or its properties might result in
altered poly(A) site use. When we used T7 RNA pol, which has little or
no affinity for processing factors, to synthesize transcripts in a HeLa
cell nuclear extract, we observed a difference in the processing
pattern. According to our results, in T7 RNA pol synthesized
transcripts, the L3 poly(A) site is used preferentially over the
proximal, but weaker, L1 site, suggesting that when the association
between the polymerase and the processing machinery is attenuated (or
nonexistent), the stronger poly(A) site is able to compete for
processing factors even when it is farther away from the promoter.
Although these results do not definitively establish the specific
involvement of the CTD of RNA pol II, they demonstrate that an
intrinsic property of the polymerase is linked to the predominant use
of the L1 site.
Past work has provided the framework for a model that explains
alternative 3' end processing in the adenovirus MLTU. For example, we
and others have demonstrated that regulatory sequences upstream and
downstream of the L1 poly(A) site are necessary for the predominant use
of the L1 site early in infection (39, 44), that splice sites are not
involved (41), and that binding of CPSF to the pre-mRNA is
stabilized by these regulatory sequences (53). Our present results
allow us to modify this model. Specifically, this work suggests that
the L1 poly(A) site also has a positional advantage in the MLTU and
that this advantage is dependent on RNA pol II. The distance between
the poly(A) sites on the viral chromosome is much greater than that in
our constructs, which would potentially give the L1 site an even
greater positional advantage with respect to 3' end processing. In
addition to effects related to RNA pol II, processing at the proximal
poly(A) site may also be enhanced because of its proximity to the RNA
5' cap structure. Cooke and Alwine (54) have demonstrated that the
processing efficiency of a pre-mRNA containing a single poly(A)
site was augmented if that pre-mRNA had a 5' cap. Furthermore, they
showed that excess 5' cap structures inhibited processing whereas cap
analogs did not, presumably because the analogs could not titrate cap
binding factors. It is conceivable that cap binding factors may
interact with the proximal poly(A) site and/or the 3' processing
machinery to enhance processing. We would note that it is possible that an interaction with cap binding factors may play a role in our system,
because the T7-transcribed pre-mRNAs in the experiment shown in
Fig. 4 are likely not capped. As a whole, then, we conclude that early
in infection processing at the L1 site is favored because of the
presence of the regulatory sequences and because of its positional advantage.
Although positional advantage may explain the preferential use of the
L1 poly(A) site early in infection, it cannot account for the fact that
the more distal sites are used roughly equally to the L1 site late in
infection. One possible explanation for the decrease in processing at
the L1 site is a change in the levels of processing factors present in
the late infected nucleus. The transcription rate of the MLTU increases
400-1000-fold late in infection, at which time viral transcripts
represent 20-40% of the mRNA in the cell (33). Conceivably, many
of the processing factors could be titrated away by the abundant viral
transcripts. In addition, translation of transcripts from cellular
genes is inhibited during the late phase of the viral infection (55), making it possible that the expression of processing factors is decreased. Indeed, investigators have demonstrated that the activity of
the processing factor CstF decreases slightly late in infection (56).
We would note, however, that a simple titration of processing factors
in and of itself cannot account for the switch, as the processing
pattern from a virus newly introduced into a late-infected cell is
still early in nature (41). This indicates that if factors are
limiting, their access to unreplicated and replicated viral chromosomes
is different. Increasing evidence suggests that mRNA 3' end
processing is intimately coupled to transcription (for reviews, see
Refs. 57 and 58); thus, altered poly(A) site use could be a reflection
of a change in the association of processing factors with the RNA pol
II holoenzyme. This hypothesis is supported by the difference we
observed in the processing pattern when RNA pol II was replaced with T7
RNA pol. Although the system used here is only an approximation, our
observation provides an insight into the mechanism by which the switch
in processing efficiency during late infection might be accomplished.
We would speculate that other mechanisms might also be involved in the
late processing switch. It is possible, for example, that unidentified
3' end processing repressors come into play during late infection,
preventing use of the promoter-proximal sites. Alternatively, an
alteration in the structure of the regulatory region of the L1 poly(A)
site could affect binding of processing factors, thus causing an
attenuation in processing efficiency at that site. Indeed, Graveley and
co-workers (59) have shown that human immunodeficiency virus
pre-mRNA structure plays an important role in poly(A) site
recognition by CPSF. It is clear that in vitro systems such
as the one we have used in the present work will be extremely useful in
sorting out the relative contribution of factors potentially affecting
poly(A) site choice.
 |
ACKNOWLEDGEMENTS |
We thank David Friedman, Kurt Gustin, Kimya
Harris, and David Engelke for critically reviewing the manuscript and
the members of our laboratory for input.
 |
FOOTNOTES |
*
This work was supported by United States Public Health
Service Grant GM34902 (to M. J. I.).The costs of publication of this article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: 6310 Cancer Center,
1500 E. Medical Center Dr., Ann Arbor, MI 48109-0942. Tel.: 734-763-9162; Fax: 734-647-9271; E-mail:
imperial@umich.edu.
Published, JBC Papers in Press, September 10, 2001, DOI 10.1074/jbc.M104709200
2
D. S. Karow, unpublished results.
 |
ABBREVIATIONS |
The abbreviations used are:
CPSF, cleavage and
polyadenylation factor;
CstF, cleavage stimulatory factor;
CTD, carboxyl-terminal domain;
pol, polymerase;
MLTU, major late
transcription unit;
MLP, major late promoter;
kb, kilobase pair(s).
 |
REFERENCES |
| 1.
|
Colgan, D. F.,
and Manley, J. L.
(1997)
Genes Dev.
11,
2755-2766[Free Full Text]
|
| 2.
|
Wahle, E.,
and Kuhn, U.
(1997)
Prog. Nucleic Acid Res. Mol. Biol.
57,
41-71[Medline]
[Order article via Infotrieve]
|
| 3.
|
Wahle, E.,
and Ruegsegger, U.
(1999)
FEMS Microbiol. Rev.
23,
277-295[Medline]
[Order article via Infotrieve]
|
| 4.
|
Chen, F.,
MacDonald, C. C.,
and Wilusz, J.
(1995)
Nucleic Acids Res.
23,
2614-2620[Abstract/Free Full Text]
|
| 5.
|
Takagaki, Y.,
and Manley, J. L.
(2000)
Mol. Cell. Biol.
20,
1515-1525[Abstract/Free Full Text]
|
| 6.
|
Bienroth, S.,
Wahle, E.,
Suter-Crazzolara, C.,
and Keller, W.
(1991)
J. Biol. Chem.
266,
19768-19776[Abstract/Free Full Text]
|
| 7.
|
Christofori, G.,
and Keller, W.
(1988)
Cell
54,
875-889[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Gilmartin, G. M.,
McDevitt, M. A.,
and Nevins, J. R.
(1988)
Genes Dev.
2,
578-587[Abstract/Free Full Text]
|
| 9.
|
Gilmartin, G. M.,
and Nevins, J. R.
(1989)
Genes Dev.
3,
2180-2190[Abstract/Free Full Text]
|
| 10.
|
Murthy, K. G.,
and Manley, J. L.
(1992)
J. Biol. Chem.
267,
14804-14811[Abstract/Free Full Text]
|
| 11.
|
Takagaki, Y.,
Ryner, L. C.,
and Manley, J. L.
(1988)
Cell
52,
731-742[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Gilmartin, G. M.,
and Nevins, J. R.
(1991)
Mol. Cell. Biol.
11,
2432-2438[Abstract/Free Full Text]
|
| 13.
|
Takagaki, Y.,
Manley, J. L.,
MacDonald, C. C.,
Wilusz, J.,
and Shenk, T.
(1990)
Genes Dev.
4,
2112-2120[Abstract/Free Full Text]
|
| 14.
|
Wilusz, J.,
and Shenk, T.
(1990)
Mol. Cell. Biol.
10,
6397-6407[Abstract/Free Full Text]
|
| 15.
|
Takagaki, Y.,
Ryner, L. C.,
and Manley, J. L.
(1989)
Genes Dev.
3,
1711-1724[Abstract/Free Full Text]
|
| 16.
|
Wahle, E.
(1991)
Cell
66,
759-768[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Wahle, E.
(1995)
Biochim. Biophys. Acta
1261,
183-194[Medline]
[Order article via Infotrieve]
|
| 18.
|
Schul, W.,
Groenhout, B.,
Koberna, K.,
Takagaki, Y.,
Jenny, A.,
Manders, E. M.,
Raska, I.,
van Driel, R.,
and de Jong, L.
(1996)
EMBO J.
15,
2883-2892[Medline]
[Order article via Infotrieve]
|
| 19.
|
Dantonel, J. C.,
Murthy, K. G.,
Manley, J. L.,
and Tora, L.
(1997)
Nature
389,
399-402[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
McCracken, S.,
Fong, N.,
Yankulov, K.,
Ballantyne, S.,
Pan, G.,
Greenblatt, J.,
Patterson, S. D.,
Wickens, M.,
and Bentley, D. L.
(1997)
Nature
385,
357-361[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Hirose, Y.,
and Manley, J. L.
(1998)
Nature
395,
93-96[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Cramer, P.,
Caceres, J. F.,
Cazalla, D.,
Kadener, S.,
Muro, A. F.,
Baralle, F. E.,
and Kornblihtt, A. R.
(1999)
Mol. Cell
4,
251-258[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Edwalds-Gilbert, G.,
Veraldi, K. L.,
and Milcarek, C.
(1997)
Nucleic Acids Res.
25,
2547-2561[Abstract/Free Full Text]
|
| 24.
|
Inoue, K.,
Hoshijima, K.,
Sakamoto, H.,
and Shimura, Y.
(1990)
Nature
344,
461-463[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Sosnowski, B. A.,
Belote, J. M.,
and McKeown, M.
(1989)
Cell
58,
449-459[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Amara, S. G.,
Jonas, V.,
Rosenfeld, M. G.,
Ong, E. S.,
and Evans, R. M.
(1982)
Nature
298,
240-244[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Kobrin, B. J.,
Milcarek, C.,
and Morrison, S. L.
(1986)
Mol. Cell. Biol.
6,
1687-1697[Abstract/Free Full Text]
|
| 28.
|
Lassman, C. R.,
Matis, S.,
Hall, B. L.,
Toppmeyer, D. L.,
and Milcarek, C.
(1992)
J. Immunol.
148,
1251-1260[Abstract]
|
| 29.
|
Veraldi, K. L.,
Arhin, G. K.,
Martincic, K.,
Chung-Ganster, L. H.,
Wilusz, J.,
and Milcarek, C.
(2001)
Mol. Cell. Biol.
21,
1228-1238[Abstract/Free Full Text]
|
| 30.
|
Lassman, C. R.,
and Milcarek, C.
(1992)
J. Immunol.
148,
2578-2585[Abstract]
|
| 31.
|
Takagaki, Y.,
Seipelt, R. L.,
Peterson, M. L.,
and Manley, J. L.
(1996)
Cell
87,
941-952[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Imperiale, M. J.,
Akusjarvi, G.,
and Leppard, K. N.
(1995)
Curr. Top. Microbiol. Immunol.
199,
139-171
|
| 33.
|
Nevins, J. R.,
and Chen-Kiang, S.
(1981)
Adv. Virus Res.
26,
1-35[Medline]
[Order article via Infotrieve]
|
| 34.
|
Nevins, J. R.,
and Darnell, J. E. J.
(1978)
Cell
15,
1477-1493[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Akusjarvi, G.,
and Persson, H.
(1981)
Nature
292,
420-426[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Nevins, J. R.,
and Wilson, M. C.
(1981)
Nature
290,
113-118[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Shaw, A. R.,
and Ziff, E. B.
(1980)
Cell
22,
905-916[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Prescott, J. C.,
and Falck-Pedersen, E.
(1992)
J. Biol. Chem.
267,
8175-8181[Abstract/Free Full Text]
|
| 39.
|
DeZazzo, J. D.,
Falck-Pedersen, E.,
and Imperiale, M. J.
(1991)
Mol. Cell. Biol.
11,
5977-5984[Abstract/Free Full Text]
|
| 40.
|
Wilson-Gunn, S. I.,
Kilpatrick, J. E.,
and Imperiale, M. J.
(1992)
J. Virol.
66,
5418-5424[Abstract/Free Full Text]
|
| 41.
|
Falck-Pedersen, E.,
and Logan, J.
(1989)
J. Virol.
63,
532-541[Abstract/Free Full Text]
|
| 42.
|
Wickens, M.,
and Stephenson, P.
(1984)
Science
226,
1045-1051[Free Full Text]
|
| 43.
|
Dignam, J. D.,
Lebovitz, R. M.,
and Roeder, R. G.
(1983)
Nucleic Acids Res.
11,
1475-1489[Abstract/Free Full Text]
|
| 44.
|
DeZazzo, J. D.,
and Imperiale, M. J.
(1989)
Mol. Cell. Biol.
9,
4951-4961[Abstract/Free Full Text]
|
| 45.
|
Chomczynski, P.,
and Sacchi, N.
(1987)
Anal. Biochem.
162,
156-159[Medline]
[Order article via Infotrieve]
|
| 46.
|
Prescott, J. C.,
Liu, L.,
and Falck-Pedersen, E.
(1997)
Mol. Cell. Biol.
17,
2207-2216[Abstract]
|
| 47.
|
de Mercoyrol, L.,
Job, C.,
and Job, D.
(1989)
Biochem. J.
258,
165-169[Medline]
[Order article via Infotrieve]
|
| 48.
|
Sousa, R.,
Chung, Y. J.,
Rose, J. P.,
and Wang, B. C.
(1993)
Nature
364,
593-599[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Sandig, V.,
Lieber, A.,
Bahring, S.,
and Strauss, M.
(1993)
Gene
131,
255-259[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Bahring, S.,
Sandig, V.,
Lieber, A.,
and Strauss, M.
(1994)
BioTechniques
16,
807-808[Medline]
[Order article via Infotrieve]
|
| 51.
|
Denome, R. M.,
and Cole, C. N.
(1988)
Mol. Cell. Biol.
8,
4829-4839[Abstract/Free Full Text]
|
| 52.
|
Manley, J. L.,
Sharp, P. A.,
and Gefter, M. L.
(1982)
J. Mol. Biol.
159,
581-599[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Gilmartin, G. M.,
Hung, S. L.,
DeZazzo, J. D.,
Fleming, E. S.,
and Imperiale, M. J.
(1996)
J. Virol.
70,
1775-1783[Abstract]
|
| 54.
|
Cooke, C.,
and Alwine, J. C.
(1996)
Mol. Cell. Biol.
16,
2579-2584[Abstract]
|
| 55.
|
Huang, J. T.,
and Schneider, R. J.
(1991)
Cell
65,
271-280[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Mann, K. P.,
Weiss, E. A.,
and Nevins, J. R.
(1993)
Mol. Cell. Biol.
13,
2411-2419[Abstract/Free Full Text]
|
| 57.
|
Bentley, D.
(1999)
Curr. Opin. Cell Biol.
11,
347-351[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Minvielle-Sebastia, L.,
and Keller, W.
(1999)
Curr. Opin. Cell Biol.
11,
352-357[CrossRef][Medline]
[Order article via Infotrieve]
|
| 59.
|
Graveley, B. R.,
Fleming, E. S.,
and Gilmartin, G. M.
(1996)
Mol. Cell. Biol.
16,
4942-4951[Abstract]
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. A. Preuss, J. T. Lam, M. Wang, C. A. Leath III, M. Kataram, P. J. Mahasreshti, R. D. Alvarez, and D. T. Curiel
Transcriptional Blocks Limit Adenoviral Replication in Primary Ovarian Tumor
Clin. Cancer Res.,
May 1, 2004;
10(9):
3189 - 3194.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|